Minimal demand leads to Ranbaxy withdrawing 4 anti-infectives, in varying strengths, from WHO prequalified list
Ranbaxy has withdrawn four anti-infectives (in varying strengths) from the WHO prequalified list citing minimal demand not commensurate with administrative outgo, as the reason for not retaining the prequalified status.
Ranbaxy has decided to take this decision as, "The demand generated through WHO PQ Status of these products in the last few years has been minimal and not commensurate with the concomitant administrative mechanism required to sustain it."
Products that are accordingly being withdrawn from the WHO prequalification list are:
-
HA 169/170/171 Aciclovir 200/400/800mg Tablets
-
HA 144/145/146 Ciprofloxacin 250/500/750mg Tablets
-
HA 147/148 Clarithromycin 250/500mg Tablets
-
HA 172/173/174/175 Fluconazole 50/100/150/200mg Capsules
Related Link: 50th Edition List of HIV/AIDS Prequalified Products & Manufacturers